Back to Search
Start Over
Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial
- Source :
- The Lancet Diabetes & Endocrinology; May 2014, Vol. 2 Issue: 5 p406-416, 11p
- Publication Year :
- 2014
-
Abstract
- The prevalence of non-alcoholic fatty liver disease is increasing worldwide and an effective and safe pharmacological treatment is needed. We investigated whether inhibition of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1, also known as HSD11B1) by RO5093151 could safely and effectively decrease liver-fat content in patients with this disorder.
Details
- Language :
- English
- ISSN :
- 22138587 and 22138595
- Volume :
- 2
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- The Lancet Diabetes & Endocrinology
- Publication Type :
- Periodical
- Accession number :
- ejs34973356
- Full Text :
- https://doi.org/10.1016/S2213-8587(13)70170-0